17080061a
HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 07, July 2017 – Food Science & Technology       » Scientists Demonstrate RNAi as an Antiviral Immunity in Mammals       » Singaporeans' Pain Costs Economy USD 6.2 billion Each Year       » China Fights Academic Paper Fraud After Peer Review Scandal       » Human Heart Tissue Grown from Stem Cells Improves Drug Testing       » Bioengineered Human Livers Mimic Natural Development       » Does Consuming Low-Fat Dairy Increase the Risk of Parkinson's Disease?      
INSIDE INDUSTRY
Daiichi Sankyo to expand its collaborative drug discovery program to Germany, Switzerland, and Austria

Daiichi Sankyo Company, Limited will expand its Take a New challenge for Drug diScovery (TaNeDS) Global Program, a collaborative drug discovery program with universities and research institutions based in Japan, to Germany, Switzerland and Austria. As part of the program, Daiichi Sankyo is seeking to work with innovative partners for research that could result in novel drug discovery candidates and novel new drugs.

The TaNeDS program is open to researchers of any nationality employed by universities, research institutes and start-up companies in Germany, Switzerland and Austria who can conduct research in those countries with projects that align with Daiichi Sankyo's research areas of interest, which include novel biologic agents (antibody drugs, etc.) for treatment of cancer, small-molecule cancer therapeutics, novel drug treatments for diabetes and complications of diabetes, novel mechanisms for genetic disorders, novel target molecules and delivery systems for nucleic acid treatments, and technology for protein x-ray crystallography.

Daiichi Sankyo and U3 Pharma GmbH (headquarters, Munich, Germany; hereafter, U3 Pharma), a wholly owned subsidiary of Daiichi Sankyo, will select institutions that match their research needs and demonstrate originality, potential and promise as drug discovery candidates.

The TaNeDS collaborative drug discovery project was launched in Japan in 2011 to help discover new lines of research through open innovation. Many researchers in Japan have applied to the program and research on selected themes is currently being conducted.

Click here for the complete issue.

NEWS CRUNCH  
news Nestlé Introduces their Singapore R&D Centre
news Vitafoods Asia Elevates 2017 Learning Programme
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy